This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Ames F.R., Cridland S.: Anticonvulsant effect of cannabidiol. South African Medical Journal, 1985, 69: 14.AmesF.R.CridlandS.: Anticonvulsant effect of cannabidiol. South African Medical Journal, 1985, 69: 14.Search in Google Scholar
Andrew J., Hill T.D.M., Walley B.J.: The development of cannabinoid based therapies for epilepsy. In: E. Murillo-Rodríguez Eso, N.A. Darmani, E. Wagner (Eds), Endocannabinoids: molecular, pharmacological, behavioral and clinical features. Oak Park, IL: Bentham Science, 2013: 164–204.AndrewJ.HillT.D.M.WalleyB.J.: The development of cannabinoid based therapies for epilepsy. In: E.Murillo-Rodríguez EsoN.A.DarmaniE.Wagner (Eds), Endocannabinoids: molecular, pharmacological, behavioral and clinical features. Oak Park, IL: Bentham Science, 2013: 164–204.Search in Google Scholar
Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S.: Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia, 2017, 58: 181–221.BialerM.JohannessenS.I.LevyR.H.PeruccaE.TomsonT.WhiteH.S.: Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia, 2017, 58: 181–221.10.1111/epi.13634Search in Google Scholar
Brodie M.J., Ben-Menachem E.: Cannabinoids for epilepsy: What do we know and where do we go? Epilepsia, 2018, 59: 291–296.BrodieM.J.Ben-MenachemE.: Cannabinoids for epilepsy: What do we know and where do we go?Epilepsia, 2018, 59: 291–296.10.1111/epi.13973Search in Google Scholar
Brodie M.J., Barry S.J., Bamagous G.A., Norrie J.D., Kwan P.: Patterns of treatment response in newly diagnosed epilepsy. Neurology, 2012, 78: 1548–1554.BrodieM.J.BarryS.J.BamagousG.A.NorrieJ.D.KwanP.: Patterns of treatment response in newly diagnosed epilepsy. Neurology, 2012, 78: 1548–1554.10.1212/WNL.0b013e3182563b19Search in Google Scholar
(CDC) Centers for Disease Control and Prevention.: Epilepsy in adults and access to care – United States, 2010. Morbidity and mortality weekly report. MMWR, 2012: 909–913.(CDC) Centers for Disease Control and Prevention.: Epilepsy in adults and access to care – United States, 2010. Morbidity and mortality weekly report. MMWR, 2012: 909–913.Search in Google Scholar
Chiurchiu V., van der Stelt M., Centonze D., Maccarrone M.: The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: clues for other neuroinflammatory diseases. Prog. Neurobiol., 2018; 160: 82–100.ChiurchiuV.van der SteltM.CentonzeD.MaccarroneM.: The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: clues for other neuroinflammatory diseases. Prog. Neurobiol., 2018; 160: 82–100.10.1016/j.pneurobio.2017.10.007Search in Google Scholar
Crippa J.A., Crippa A., Hallak J.E., Martín-Santos R., Zuardi A.W.: 9-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol. Frontiers in pharmacology, 2016, 7: 359.CrippaJ.A.CrippaA.HallakJ.E.Martín-SantosR.ZuardiA.W.: 9-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol. Frontiers in pharmacology, 2016, 7: 359.10.3389/fphar.2016.00359Search in Google Scholar
Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R. et al.: Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology, 1980, 21: 175–185.CunhaJ.M.CarliniE.A.PereiraA.E.RamosO.L.PimentelC.GagliardiR.: Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology, 1980, 21: 175–185.10.1159/000137430Search in Google Scholar
Detyniecki K., Hirsch L.J.: Cannabidiol for epilepsy: trying to see through the haze. Lancet Neurol., 2016, 15: 235–237.DetynieckiK.HirschL.J.: Cannabidiol for epilepsy: trying to see through the haze. Lancet Neurol., 2016, 15: 235–237.10.1016/S1474-4422(16)00002-8Search in Google Scholar
Devinsky O., Patel A.D., Cross J.H., Villanueva V., Wirrell E.C., Privitera M. et al.: Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N. Engl. J. Med., 2018, 378: 1888–1897.DevinskyO.PatelA.D.CrossJ.H.VillanuevaV.WirrellE.C.PriviteraM.: Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N. Engl. J. Med., 2018, 378: 1888–1897.10.1056/NEJMoa1714631Search in Google Scholar
Devinsky O., Cross J.H., Laux L., Marsh E., Miller I., Nabbout R. et al.: Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N. Engl. J. Med., 2017, 376: 2011–2020.DevinskyO.CrossJ.H.LauxL.MarshE.MillerI.NabboutR.: Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N. Engl. J. Med., 2017, 376: 2011–2020.10.1056/NEJMoa1611618Search in Google Scholar
Devinsky O., Marsh E., Friedman D., Thiele E., Laux L., Sullivan J. et al.: Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol., 2015, 15: 270–278.DevinskyO.MarshE.FriedmanD.ThieleE.LauxL.SullivanJ.: Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol., 2015, 15: 270–278.10.1016/S1474-4422(15)00379-8Search in Google Scholar
Devinsky O., Cilio M.R., Cross H., Fernandez-Ruiz J., French J., Hill C. et al.: Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 2014, 55: 791–802.DevinskyO.CilioM.R.CrossH.Fernandez-RuizJ.FrenchJ.HillC.: Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 2014, 55: 791–802.10.1111/epi.12631Search in Google Scholar
(FDA) U.S. Food and Drug Administration.: FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. 2018. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm611046.htm (accessed Nov. 12, 2018).(FDA) U.S. Food and Drug Administration.: FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. 2018. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm611046.htm (accessed Nov. 12, 2018).Search in Google Scholar
Friedman D., Cilio M.R., Tilton N.: The effect of epidiolex (cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment-resistant epilepsy in an expanded access program. Presented at the annual meeting of the American Epilepsy Society, Seattle, December 5–9, 2014. Abstract.FriedmanD.CilioM.R.TiltonN.: The effect of epidiolex (cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment-resistant epilepsy in an expanded access program. Presented at the annual meeting of the American Epilepsy Society, Seattle, December 5–9, 2014. Abstract.Search in Google Scholar
Gloss D., Vickrey B.: Cannabinoids for epilepsy. Cochrane Database Syst. Rev., 2014, 3: CD009270.GlossD.VickreyB.: Cannabinoids for epilepsy. Cochrane Database Syst. Rev., 2014, 3: CD009270.10.1002/14651858.CD009270.pub3Search in Google Scholar
Gowers W.: Epilepsy and other chronic convulsive disorders. London, Churchill 1881: 223.GowersW.: Epilepsy and other chronic convulsive disorders. London, Churchill1881: 223.Search in Google Scholar
Gupta S.: Weed. In: S. Gupta (ed.). CNN, 2013 (see video promotion for program at http://www.cnn.com/ videos/bestoftv/2013/08/05/gupta-weed-promo.cnn).GuptaS.: Weed. In: S.Gupta (ed.). CNN, 2013 (see video promotion for program at http://www.cnn.com/ videos/bestoftv/2013/08/05/gupta-weed-promo.cnn).Search in Google Scholar
Hall W., Solowij N.: Adverse effects of cannabis. Lancet, 1998, 352: 1611–1616.HallW.SolowijN.: Adverse effects of cannabis. Lancet, 1998, 352: 1611–1616.10.1016/S0140-6736(98)05021-1Search in Google Scholar
Henderson G.E., Churchill L.R., Davis A.M., Easter M.M., Grady C., Joffe S. et al.: Clinical trials and medical care: defining the therapeutic misconception. PLoS Med., 2007, 4: e324.HendersonG.E.ChurchillL.R.DavisA.M.EasterM.M.GradyC.JoffeS.: Clinical trials and medical care: defining the therapeutic misconception. PLoS Med., 2007, 4: e324.10.1371/journal.pmed.0040324208264118044980Search in Google Scholar
Hill T.D.M., Cascio M.-G., Romano B., Duncan M., Pertwee R.G., Williams C.M. et al.: Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br. J. Pharmacol., 2013, 17: 679–692.HillT.D.M.CascioM.-G.RomanoB.DuncanM.PertweeR.G.WilliamsC.M.: Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br. J. Pharmacol., 2013, 17: 679–692.10.1111/bph.12321379200523902406Search in Google Scholar
Iannotti F.A., Di Marzo V., Petrosino S.: Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. Prog. Lipid. Res., 2016, 62: 107–128.IannottiF.A.Di MarzoV.PetrosinoS.: Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. Prog. Lipid. Res., 2016, 62: 107–128.10.1016/j.plipres.2016.02.00226965148Search in Google Scholar
Iannotti F.A., Hill C.L., Leo A., Alhusaini A., Soubrane C., Mazzarella E. et al.: Nonpsychotropic plant cannabinoids, cannabidavarin (CBDV) and cannabidiol (CBD) activate and desensitise transient receptor potential vanilloid1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem. Neurosci., 2014, 5: 1131–1141.IannottiF.A.HillC.L.LeoA.AlhusainiA.SoubraneC.MazzarellaE.: Nonpsychotropic plant cannabinoids, cannabidavarin (CBDV) and cannabidiol (CBD) activate and desensitise transient receptor potential vanilloid1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem. Neurosci., 2014, 5: 1131–1141.10.1021/cn500052425029033Search in Google Scholar
Ibeas Bih C., Chen T., Nunn A.V., Bazelot M., Dallas M., Whalley B.J.: Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics, 2015, 12: 699–730.Ibeas BihC.ChenT.NunnA.V.BazelotM.DallasM.WhalleyB.J.: Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics, 2015, 12: 699–730.10.1007/s13311-015-0377-3460418226264914Search in Google Scholar
Koppel B.S., Brust J.C., Fife T., Bronstein J., Youssof S., Gronseth G. et al.: Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2014, 82: 1556–1563.KoppelB.S.BrustJ.C.FifeT.BronsteinJ.YoussofS.GronsethG.: Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2014, 82: 1556–1563.10.1212/WNL.0000000000000363401146524778283Search in Google Scholar
Kwan P., Brodie M.J.: Early identification of refractory epilepsy. N. Engl. J. Med., 2000, 342: 314–319.KwanP.BrodieM.J.: Early identification of refractory epilepsy. N. Engl. J. Med., 2000, 342: 314–319.10.1056/NEJM20000203342050310660394Search in Google Scholar
Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Hauser A.W., Mathern G. et al.: Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51: 1069–1077. doi: 10.1111/j.1528-1167.2009.02397.x.KwanP.ArzimanoglouA.BergA.T.BrodieM.J.HauserA.W.MathernG.: Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51: 1069–1077. doi: 10.1111/j.1528-1167.2009.02397.x.Open DOISearch in Google Scholar
Leo A., Russo E., Elia M.: Cannabidiol and epilepsy: Rationale and therapeutic potential. Pharmacol. Res., 2016, 107: 85–92.LeoA.RussoE.EliaM.: Cannabidiol and epilepsy: Rationale and therapeutic potential. Pharmacol. Res., 2016, 107: 85–92.10.1016/j.phrs.2016.03.005Search in Google Scholar
Lorenzetti V., Solowij N., Whittle S., Fornito A., Lubman D.I., Pantelis C. et al.: Gross morphological brain changes with chronic, heavy cannabis use. Br. J. Psychiatry, 2015, 206: 77–78.LorenzettiV.SolowijN.WhittleS.FornitoA.LubmanD.I.PantelisC.: Gross morphological brain changes with chronic, heavy cannabis use. Br. J. Psychiatry, 2015, 206: 77–78.10.1192/bjp.bp.114.151407Search in Google Scholar
Maccarrone M., Maldonado R., Casas M., Henze T., Centonze D.: Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? Expert Rev. Clin. Pharmacol., 2017, 10: 443–455.MaccarroneM.MaldonadoR.CasasM.HenzeT.CentonzeD.: Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?Expert Rev. Clin. Pharmacol., 2017, 10: 443–455.10.1080/17512433.2017.1292849Search in Google Scholar
Maccarrone M., Bab I, Bíró T., Cabral G.A., Dey S.K., Di Marzo V. et al.: Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol. Sci., 2015, 36: 277–296.MaccarroneM.BabIBíróT.CabralG.A.DeyS.K.Di MarzoV.: Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol. Sci., 2015, 36: 277–296.10.1016/j.tips.2015.02.008Search in Google Scholar
Martin P., Consroe P.: Cannabinoid induced behavioral convulsions in rabbits. Science, 1976, 194: 965–967.MartinP.ConsroeP.: Cannabinoid induced behavioral convulsions in rabbits. Science, 1976, 194: 965–967.10.1126/science.982057Search in Google Scholar
Mathern G.W., Beninsig L., Nehlig A.: Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: result of Epilepsia’s survey. Epilepsia, 2015, 56: 1–6.MathernG.W.BeninsigL.NehligA.: Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: result of Epilepsia’s survey. Epilepsia, 2015, 56: 1–6.10.1111/epi.12843Search in Google Scholar
Mechoulam R., Carlini E.A.: Toward drugs derived from cannabis. Naturwissenschaften, 1978, 65: 174–179.MechoulamR.CarliniE.A.: Toward drugs derived from cannabis. Naturwissenschaften, 1978, 65: 174–179.10.1007/BF00450585Search in Google Scholar
Mechoulam R., Shvo Y.: Hashish – I: the structure of cannabidiol. Tetrahedron, 1963, 19: 2073–2078.MechoulamR.ShvoY.: Hashish – I: the structure of cannabidiol. Tetrahedron, 1963, 19: 2073–2078.10.1016/0040-4020(63)85022-XSearch in Google Scholar
Patsalos P.N., Perucca E.: Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol., 2003, 2: 347–356.PatsalosP.N.PeruccaE.: Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol., 2003, 2: 347–356.10.1016/S1474-4422(03)00409-5Search in Google Scholar
Perucca P., Gilliam F.G.: Adverse effects of antiepileptic drugs. Lancet Neurol., 2012, 11: 792–802.PeruccaP.GilliamF.G.: Adverse effects of antiepileptic drugs. Lancet Neurol., 2012, 11: 792–802.10.1016/S1474-4422(12)70153-9Search in Google Scholar
Press C.A., Knupp K.G., Chapman K.E.: Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav., 2015, 45: 49–52.PressC.A.KnuppK.G.ChapmanK.E.: Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav., 2015, 45: 49–52.10.1016/j.yebeh.2015.02.043Search in Google Scholar
Radwan M.M., Elsohly M.A., Slade D., Ahmed S.A., Khan I.A., Ross S.A.: Biologically active cannabinoids from high potency Cannabis sativa. Journal of Natural Products, 2009, 72: 906–911.RadwanM.M.ElsohlyM.A.SladeD.AhmedS.A.KhanI.A.RossS.A.: Biologically active cannabinoids from high potency Cannabis sativa. Journal of Natural Products, 2009, 72: 906–911.10.1021/np900067kSearch in Google Scholar
Reddy D.S., Golub V.M.: The pharmacological basis of cannabis therapy for epilepsy. J. Pharmacol. Exp. Ther., 2016, 357: 45–55.ReddyD.S.GolubV.M.: The pharmacological basis of cannabis therapy for epilepsy. J. Pharmacol. Exp. Ther., 2016, 357: 45–55.10.1124/jpet.115.230151Search in Google Scholar
Reynolds J.R.: Epilepsy: its symptoms, treatment, and relation to other chronic convulsive diseases. John Churchill, London 1861.ReynoldsJ.R.: Epilepsy: its symptoms, treatment, and relation to other chronic convulsive diseases. John Churchill, London1861.Search in Google Scholar
Rheims S., Cucherat M., Arzimanoglou A., Ryvlin P.: Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med., 2008, 5: e166.RheimsS.CucheratM.ArzimanoglouA.RyvlinP.: Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med., 2008, 5: e166.10.1371/journal.pmed.0050166Search in Google Scholar
Rosenberg E.C., Tsien R.W., Whalley B., Devinsky O.: Cannabinoids and epilepsy. Neurotherapeutics, 2015, 12: 747–768.RosenbergE.C.TsienR.W.WhalleyB.DevinskyO.: Cannabinoids and epilepsy. Neurotherapeutics, 2015, 12: 747–768.10.1007/s13311-015-0375-5Search in Google Scholar
Santos R.G. dos, Hallak J.E., Leite J.P., Zuardi A.W., Crippa J.A.: Phytocannabinoids and epilepsy. J. Clin. Pharm. Ther., 2015, 40: 135–143.SantosR.G. dosHallakJ.E.LeiteJ.P.ZuardiA.W.CrippaJ.A.: Phytocannabinoids and epilepsy. J. Clin. Pharm. Ther., 2015, 40: 135–143.10.1111/jcpt.12235Search in Google Scholar
Scuderi C., Filippis D.D., Iuvone T., Blasio A., Steardo A., Esposito G.: Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother. Res., 2009, 23: 597–602. doi: 10.1002/ptr.2625.ScuderiC.FilippisD.D.IuvoneT.BlasioA.SteardoA.EspositoG.: Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother. Res., 2009, 23: 597–602. doi: 10.1002/ptr.2625.Open DOISearch in Google Scholar
Stadnicki S.W., Schaeppi U., Rosenkrantz H., Braude M.C.: Delta 9-tetrahydrocannabinol: subcortical spike bursts and motor manifestations in a Fischer rat treated orally for 109 days. Life Sci., 1974, 14: 463–472.StadnickiS.W.SchaeppiU.RosenkrantzH.BraudeM.C.: Delta 9-tetrahydrocannabinol: subcortical spike bursts and motor manifestations in a Fischer rat treated orally for 109 days. Life Sci., 1974, 14: 463–472.10.1016/0024-3205(74)90361-0Search in Google Scholar
Stout S.M., Cimino N.M.: Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab. Rev., 2014, 46: 86–95.StoutS.M.CiminoN.M.: Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab. Rev., 2014, 46: 86–95.10.3109/03602532.2013.84926824160757Search in Google Scholar
Thiele E.A., Marsh E.D., French J.A., Mazurkiewicz-Beldzinska M., Benbadis S.R., Joshi C. et al.: Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWP-CARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 2018, 391: 1085–1096.ThieleE.A.MarshE.D.FrenchJ.A.Mazurkiewicz-BeldzinskaM.BenbadisS.R.JoshiC.: Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWP-CARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 2018, 391: 1085–1096.10.1016/S0140-6736(18)30136-3Search in Google Scholar
Trembly B., Sherman M.: Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana ’90 International Conference on Cannabis and Cannabinoids. 1990 July 8–11; Kolympari, Crete. International Association for Cannabinoid Medicines, 1990: section 2, p. 5.TremblyB.ShermanM.: Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana ’90 International Conference on Cannabis and Cannabinoids. 1990 July 8–11; Kolympari, Crete. International Association for Cannabinoid Medicines, 1990: section 2, p. 5.Search in Google Scholar
Volkow N.D., Baler R.D., Compton W.M., Weiss S.R.: Adverse health effects of marijuana use. N. Engl. J. Med., 2014, 370: 2219–2227.VolkowN.D.BalerR.D.ComptonW.M.WeissS.R.: Adverse health effects of marijuana use. N. Engl. J. Med., 2014, 370: 2219–2227.10.1056/NEJMra1402309482733524897085Search in Google Scholar
Weimer K., Gulewitsch M.D., Schlarb A.A., Schwille-Kiuntke J., Klosterhalfen S., Enck P.: Placebo effects in children: a review. Pediatr. Res., 2013, 74: 96–102.WeimerK.GulewitschM.D.SchlarbA.A.Schwille-KiuntkeJ.KlosterhalfenS.EnckP.: Placebo effects in children: a review. Pediatr. Res., 2013, 74: 96–102.10.1038/pr.2013.6623598811Search in Google Scholar
Zendulka O., Dovrtelova G., Noskova K., Turjap M., Šulcová A., Hanuš L. et al.: Cannabinoids and cytochrome P450 interactions. Curr. Drug. Metab., 2016, 17: 206–226.ZendulkaO.DovrtelovaG.NoskovaK.TurjapM.ŠulcováA.HanušL.: Cannabinoids and cytochrome P450 interactions. Curr. Drug. Metab., 2016, 17: 206–226.10.2174/138920021766615121014205126651971Search in Google Scholar
